Chengdong Qin

744 total citations
19 papers, 545 citations indexed

About

Chengdong Qin is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Chengdong Qin has authored 19 papers receiving a total of 545 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cancer Research, 12 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Chengdong Qin's work include Breast Cancer Treatment Studies (5 papers), HER2/EGFR in Cancer Research (4 papers) and Advanced Breast Cancer Therapies (3 papers). Chengdong Qin is often cited by papers focused on Breast Cancer Treatment Studies (5 papers), HER2/EGFR in Cancer Research (4 papers) and Advanced Breast Cancer Therapies (3 papers). Chengdong Qin collaborates with scholars based in China and Ethiopia. Chengdong Qin's co-authors include De-Ning Ma, Xiao‐Dong Zhu, Chenghao Wang, Zhao–You Tang, Dongmei Gao, Hui‐Chuan Sun, Manqing Cao, Ning Zhang, Yiming Zhao and Weiping Zhu and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Frontiers in Immunology.

In The Last Decade

Chengdong Qin

17 papers receiving 538 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Chengdong Qin 358 303 105 52 45 19 545
Manqing Cao 421 1.2× 309 1.0× 125 1.2× 23 0.4× 57 1.3× 17 601
Xihu Qin 309 0.9× 228 0.8× 56 0.5× 16 0.3× 60 1.3× 32 448
Diana Becker 237 0.7× 127 0.4× 132 1.3× 59 1.1× 64 1.4× 22 426
Yuchao He 393 1.1× 303 1.0× 112 1.1× 38 0.7× 121 2.7× 25 593
Tao Song 238 0.7× 140 0.5× 111 1.1× 20 0.4× 54 1.2× 28 506
Clifford C. Nwaeburu 272 0.8× 196 0.6× 218 2.1× 14 0.3× 40 0.9× 9 473
Jiongqiang Huang 272 0.8× 153 0.5× 116 1.1× 32 0.6× 44 1.0× 15 425
Junwei Song 547 1.5× 287 0.9× 137 1.3× 45 0.9× 81 1.8× 18 712

Countries citing papers authored by Chengdong Qin

Since Specialization
Citations

This map shows the geographic impact of Chengdong Qin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengdong Qin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengdong Qin more than expected).

Fields of papers citing papers by Chengdong Qin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chengdong Qin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengdong Qin. The network helps show where Chengdong Qin may publish in the future.

Co-authorship network of co-authors of Chengdong Qin

This figure shows the co-authorship network connecting the top 25 collaborators of Chengdong Qin. A scholar is included among the top collaborators of Chengdong Qin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chengdong Qin. Chengdong Qin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Liu, Siyuan, et al.. (2025). Roles of macrophages and monocytes in resistance to immunotherapy in breast cancers. Postgraduate Medical Journal. 101(1202). 1242–1247. 1 indexed citations
2.
Xu, Zheng, et al.. (2025). The potential benefits of radiotherapy in elderly patients with early-stage triple-negative breast cancer. Frontiers in Medicine. 11. 1525425–1525425.
3.
Hu, Lihong, et al.. (2025). Ferroptosis in TNBC: interplay with tumor-infiltrating immune cells and therapeutic implications. Molecular and Cellular Biochemistry. 480(9). 5029–5039.
4.
5.
Qin, Chengdong, Siyuan Liu, Shiqi Zhou, et al.. (2023). Tanshinone IIA promotes vascular normalization and boosts Sorafenib’s anti-hepatoma activity via modulating the PI3K-AKT pathway. Frontiers in Pharmacology. 14. 1189532–1189532. 9 indexed citations
6.
Qin, Chengdong, Siyuan Liu, Xianghou Xia, et al.. (2023). PIK3C2A is a prognostic biomarker that is linked to immune infiltrates in kidney renal clear cell carcinoma. Frontiers in Immunology. 14. 1114572–1114572. 3 indexed citations
7.
Yu, Xingfei, Chen Wang, Yabing Zheng, et al.. (2021). Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World. Frontiers in Oncology. 11. 1 indexed citations
8.
Ding, Yuqin, Xingfei Yu, Dehong Zou, et al.. (2020). Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer. PLoS ONE. 15(4). e0231895–e0231895. 25 indexed citations
9.
Zheng, Yurong, Xiaowen Ding, Dehong Zou, et al.. (2020). The treatment option of progressive disease in breast cancer during neoadjuvant chemotherapy: a single-center experience. Cancer Biology & Therapy. 21(8). 675–687. 4 indexed citations
10.
Zhang, Ning, Hui Li, Chengdong Qin, et al.. (2019). Insufficient radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells via upregulating flotillin proteins. Journal of Cancer Research and Clinical Oncology. 145(4). 895–907. 44 indexed citations
11.
Zheng, Yurong, Xiaowen Ding, Dehong Zou, et al.. (2019). The treatment option of progressive disease in breast cancer during neoadjuvant chemotherapy: A single-center experience.. Journal of Clinical Oncology. 37(15_suppl). e12082–e12082. 1 indexed citations
12.
Shi, Dong-Min, Xinyu Bian, Chengdong Qin, & Wei‐Zhong Wu. (2018). miR-106b-5p promotes stem cell-like properties of hepatocellular carcinoma cells by targeting PTEN via PI3K/Akt pathway. OncoTargets and Therapy. Volume 11. 571–585. 50 indexed citations
13.
Qin, Chengdong, De-Ning Ma, Shi-Zhe Zhang, et al.. (2018). The Rho GTPase Rnd1 inhibits epithelial–mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target. Cell Death and Disease. 9(5). 486–486. 21 indexed citations
14.
Cao, Manqing, A‐Bin You, Xiao‐Dong Zhu, et al.. (2018). miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. Journal of Hematology & Oncology. 11(1). 12–12. 177 indexed citations
15.
Qin, Chengdong, De-Ning Ma, Zhenggang Ren, et al.. (2017). Astragaloside IV inhibits metastasis in hepatoma cells through the suppression of epithelial-mesenchymal transition via the Akt/GSK-3β/β-catenin pathway. Oncology Reports. 37(3). 1725–1735. 43 indexed citations
16.
Wang, Chenghao, Xiao‐Dong Zhu, De-Ning Ma, et al.. (2017). Flot2 promotes tumor growth and metastasis through modulating cell cycle and inducing epithelial-mesenchymal transition of hepatocellular carcinoma.. PubMed. 7(5). 1068–1083. 29 indexed citations
17.
Ma, De-Ning, Zong‐Tao Chai, Xiao‐Dong Zhu, et al.. (2016). MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2. Journal of Hematology & Oncology. 9(1). 1–1. 102 indexed citations
18.
Li, Jinghuan, Yingcong Wang, Chengdong Qin, et al.. (2016). Over expression of hyaluronan promotes progression of HCC via CD44-mediated pyruvate kinase M2 nuclear translocation.. PubMed. 6(2). 509–21. 14 indexed citations
19.
Ye, Bo‐Gen, Hui‐Chuan Sun, Xiao‐Dong Zhu, et al.. (2016). Reduced expression of CD109 in tumor-associated endothelial cells promotes tumor progression by paracrine interleukin-8 in hepatocellular carcinoma. Oncotarget. 7(20). 29333–29345. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Manqing Cao Breakdown of academic impact, for papers by Xihu Qin Breakdown of academic impact, for papers by Diana Becker Breakdown of academic impact, for papers by Yuchao He Breakdown of academic impact, for papers by Tao Song Breakdown of academic impact, for papers by Clifford C. Nwaeburu Breakdown of academic impact, for papers by Jiongqiang Huang Breakdown of academic impact, for papers by Junwei Song
Rankless by CCL
2026